Received Oct 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
coughing; Runny nose; headache; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of cough in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, several days after receiving Arexvy, the patient experienced cough (Verbatim: coughing), runny nose (Verbatim: Runny nose) and headache (Verbatim: headache). The outcome of the cough, runny nose and headache were resolving. It was unknown if the reporter considered the cough, runny nose and headache to be related to Arexvy. It was unknown if the company considered the cough, runny nose and headache to be related to Arexvy. Additional Information: GSK Receipt Date: 24-SEP-2025 This case was reported by a patient via interactive digital media. The patient mentioned he/she got RSV vaccine (Arexvy) and a few days later experienced coughing, runny nose, headache and no fever. The patient reported he/she was getting better. The batch number was not provided, and we are unable to contact the reporter.